KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Interest & Investment Income (2016 - 2025)

BeOne Medicines (ONC) has disclosed Interest & Investment Income for 5 consecutive years, with $58.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income rose 96.3% to $58.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $70.5 million, a 1.24% increase, with the full-year FY2025 number at $70.5 million, up 1.24% from a year prior.
  • Interest & Investment Income was $58.1 million for Q4 2025 at BeOne Medicines, up from $3.0 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $58.1 million in Q4 2025 to a low of $3.0 million in Q3 2025.
  • A 3-year average of $18.5 million and a median of $13.2 million in 2024 define the central range for Interest & Investment Income.
  • Biggest YoY gain for Interest & Investment Income was 96.3% in 2025; the steepest drop was 73.56% in 2025.
  • BeOne Medicines' Interest & Investment Income stood at $26.6 million in 2023, then grew by 11.12% to $29.6 million in 2024, then soared by 96.3% to $58.1 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Interest & Investment Income are $58.1 million (Q4 2025), $3.0 million (Q3 2025), and $3.5 million (Q2 2025).